Safety and Efficacy of AS101 1% Oral Solution in Patients With Neovascular Age-Related Macular Degeneration (AMD)

NCT03216538 · clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
COMPLETED
Status
20
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Feramda